- Home
- PRQR vs ACIU Comparison
PRQR vs ACIU Comparison
Compare PRQR & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- ACIU
- Stock Information
- Founded
- PRQR 2012
- ACIU 2003
- Country
- PRQR Netherlands
- ACIU Switzerland
- Employees
- PRQR N/A
- ACIU N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- PRQR Health Care
- ACIU Health Care
- Exchange
- PRQR Nasdaq
- ACIU Nasdaq
- Market Cap
- PRQR 224.4M
- ACIU 213.3M
- IPO Year
- PRQR 2014
- ACIU 2016
- Fundamental
- Price
- PRQR $2.36
- ACIU $3.53
- Analyst Decision
- PRQR Strong Buy
- ACIU Strong Buy
- Analyst Count
- PRQR 8
- ACIU 2
- Target Price
- PRQR $8.88
- ACIU $10.00
- AVG Volume (30 Days)
- PRQR 403.1K
- ACIU 262.9K
- Earning Date
- PRQR 11-06-2025
- ACIU 11-04-2025
- Dividend Yield
- PRQR N/A
- ACIU N/A
- EPS Growth
- PRQR N/A
- ACIU N/A
- EPS
- PRQR N/A
- ACIU N/A
- Revenue
- PRQR $20,129,184.00
- ACIU $36,362,036.00
- Revenue This Year
- PRQR N/A
- ACIU N/A
- Revenue Next Year
- PRQR N/A
- ACIU $1,022.98
- P/E Ratio
- PRQR N/A
- ACIU N/A
- Revenue Growth
- PRQR 8.65
- ACIU 86.71
- 52 Week Low
- PRQR $1.07
- ACIU $1.43
- 52 Week High
- PRQR $4.62
- ACIU $3.99
- Technical
- Relative Strength Index (RSI)
- PRQR 57.39
- ACIU 68.67
- Support Level
- PRQR $2.25
- ACIU $2.70
- Resistance Level
- PRQR $2.54
- ACIU $3.99
- Average True Range (ATR)
- PRQR 0.13
- ACIU 0.29
- MACD
- PRQR 0.02
- ACIU 0.09
- Stochastic Oscillator
- PRQR 70.31
- ACIU 80.31
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.